Show simple item record

dc.contributor.authorAli-Sisto Toni
dc.contributor.authorTolmunen Tommi
dc.contributor.authorViinamäki Heimo
dc.contributor.authorMäntyselkä Pekka
dc.contributor.authorValkonen-Korhonen Minna
dc.contributor.authorKoivumaa-Honkanen Heli
dc.contributor.authorHonkalampi Kirsi
dc.contributor.authorRuusunen Anu
dc.contributor.authorNandania Jatin
dc.contributor.authorVelagapudi Vidya
dc.contributor.authorLehto Soili M
dc.date.accessioned2018-03-23T08:26:56Z
dc.date.available2018-03-23T08:26:56Z
dc.date.issued2017
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6204
dc.description.abstractBackground Major depressive disorder (MDD) is characterized by increased oxidative and nitrosative stress. We compared nitric oxide metabolism, i.e., the global arginine bioavailability ratio (GABR) and related serum amino acids, between MDD patients and non-depressed controls, and between remitted and non-remitted MDD patients. Methods Ninety-nine MDD patients and 253 non-depressed controls, aged 20–71 years, provided background data via questionnaires. Fasting serum samples were analyzed using ultra-performance liquid chromatography coupled to mass spectrometry to determine the serum levels of ornithine, arginine, citrulline, and symmetric and asymmetric dimethylarginine. GABR was calculated as arginine divided by the sum of ornithine plus citrulline. We compared the above measures between: 1) MDD patients and controls, 2) remitted (n=33) and non-remitted (n = 45) MDD patients, and 3) baseline and follow-up within the remitted and non-remitted groups. Results Lower arginine levels (OR 0.98, 95% CI 0.97–0.99) and lower GABR (OR 0.13, 95% CI 0.03–0.50) were associated with the MDD vs. the non-depressed group after adjustments for potential confounders. The remitted group showed a decrease in GABR, arginine, and symmetric dimethylarginine, and an increase in ornithine after the follow-up compared with within-group baseline values. The non-remitted group displayed an increase in arginine and ornithine levels and a decrease in GABR. No significant differences were recorded between the remitted and non-remitted groups. Limitations The MDD group was not medication-free. Conclusions Arginine bioavailability may be decreased in MDD. This could impair the production of nitric oxide, and thus add to oxidative stress in the central nervous system.
dc.language.isoEN
dc.publisherElsevier BV
dc.relation.ispartofseriesJOURNAL OF AFFECTIVE DISORDERS (AMSTERDAM)
dc.relation.urihttp://dx.doi.org/10.1016/j.jad.2017.12.030
dc.rightsCC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectmajor depressive disorder
dc.subjectarginine
dc.subjectcitrulline
dc.subjectornithine
dc.subjectglobal arginine bioavailability ratio
dc.titleGlobal arginine bioavailability ratio is decreased in patients with major depressive disorder
dc.description.versionfinal draft
dc.contributor.departmentSchool of Medicine / Clinical Medicine
dc.contributor.departmentSchool of Educational Sciences and Psychology / Psychology,School of Medicine / Public Health
uef.solecris.id51951780en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© Elsevier B.V.
dc.relation.doi10.1016/j.jad.2017.12.030
dc.description.reviewstatuspeerReviewed
dc.format.pagerange145-151
dc.relation.issn0165-0327
dc.relation.volume229
dc.rights.accesslevelopenAccess
dc.type.okmA1
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record